Kiadis announces new data related to its K-NK cell therapy platform presented today at the SITC Annual Meeting
12 nov. 2020 01h00 HE
|
Kiadis Pharma N.V.
Data presented support the potential of combining oncolytic virotherapy along with PM21-NK cell adoptive therapy against lung cancer Amsterdam, The Netherlands, November 12, 2020 – Kiadis Pharma N.V....
Sanofi offers to acquire Kiadis for €308 million
02 nov. 2020 01h00 HE
|
Kiadis Pharma N.V.
This is a joint press release by Sanofi ("Sanofi") and Kiadis Pharma N.V. ("Kiadis"), pursuant to the provisions of Section 4, paragraphs 1 and 3, Section 5, paragraph 1 and Section 7, paragraph 4 of...
Kiadis announces presentation at the 2020 Society for Immunotherapy of Cancer Annual Meeting
26 oct. 2020 02h00 HE
|
Kiadis Pharma N.V.
Amsterdam, The Netherlands, October 26, 2020 – Kiadis Pharma N.V. ("Kiadis" or the "Company") (Euronext Amsterdam and Brussels: KDS), a clinical-stage biopharmaceutical company developing innovative...
Kiadis announces the placement of €5 million convertible bonds with Kreos
01 oct. 2020 01h00 HE
|
Kiadis Pharma N.V.
9% secured convertible bonds replace €5 million in Kreos debtConversion price €2 per share Remaining Kreos debt facilities reduced to €1.6 million Amsterdam, The Netherlands, October 1, 2020 –...
Kiadis announces results for the six months ended June 30, 2020 and significant progress made to date in 2020 in all development programs
30 sept. 2020 01h00 HE
|
Kiadis Pharma N.V.
K-NK002 (HSCT): IND approved to enter Phase 2 development K-NK003 (AML R/R): IND approved and multiple patients enrolled for Phase 1 investigator initiated trial for treatment of relapsed/refractory...
Kiadis and Gulf Coast Regional Blood Center announce collaboration to provide universal donor material for K-NK cell therapy programs
28 sept. 2020 01h00 HE
|
Kiadis Pharma N.V.
Collaboration marks first contractual partnership with supplier of universal donor material Amsterdam, The Netherlands, September 28, 2020 – Kiadis Pharma N.V. ("Kiadis" or the "Company")...
Kiadis receives $9.5 million from the Advanced Regenerative Manufacturing Institute’s BioFabUSA Program to fund Kiadis K-NK cell COVID-19 therapy
15 sept. 2020 01h00 HE
|
Kiadis Pharma N.V.
Funding for COVID-19 research and development program (K-NK-ID101), to investigate the potential to establish it as a universal countermeasure to fight COVID-19 and future pandemicsFunding obtained...
Kiadis announces U.S. FDA approval of the Abigail Wexner Research Institute at Nationwide Children’s Hospital’s IND for a COVID-19 clinical trial with off-the-shelf K-NK cells using Kiadis’ proprietary platforms
14 sept. 2020 01h00 HE
|
Kiadis Pharma N.V.
Amsterdam, The Netherlands, September 14, 2020 – Kiadis Pharma N.V. (“Kiadis” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical-stage biopharmaceutical company developing innovative...
Kiadis announces investor events for September 2020
03 sept. 2020 01h00 HE
|
Kiadis Pharma N.V.
Company announces Notice of Results for the six months ended June 30, 2020 Amsterdam, The Netherlands, September 3, 2020 – Kiadis Pharma N.V. (“Kiadis” or...
Kiadis announces new data demonstrating FC21-NK cells were well tolerated and showed encouraging signs of antitumor and suspected antimicrobial activity in 13 patients with relapsed/refractory acute myeloid leukemia (R/R AML)
29 août 2020 06h30 HE
|
Kiadis Pharma N.V.
New data will be presented in an e-poster today at the Virtual Edition of the 46th EBMT Annual Meeting Amsterdam, The Netherlands, August 29, 2020 – Kiadis Pharma N.V. (“Kiadis” or the “Company”)...